COLLABORATE El Meu Clínic .This link opens in a new tab.
COLLABORATE El Meu Clínic .This link opens in a new tab.
Make a donation
Navigation thread
Navigation thread
Biomarkers and laboratory precision medicine in hepatology, metabolism, and rare diseases (HEMERA-Lab)
Make a donation

Featured projects

  • Identification of key molecules with antifibrotic effects from the alveolar type II cell secretome for the development of new therapies for idiopathic pulmonary fibrosis

    Principal investigator: Anna Serrano Mollar, Pedro Melgar Lesmes.
    Funder: Marato TV3.
    Code: 202535-30.
    Duration: 27/03/2026 - 26/03/2029

  • Treatment of metabolic liver disease using gold nanoenzymes with multicatalytic activity

    Principal investigator: Gregori Casals Mercadal.
    Funder: Instituto de Salud Carlos III (ISCIII).
    Code: PI24/00688.
    Duration: 01/01/2025 - 31/12/2027

  • CRINGENES – A new dimension in newborn screening: pilot study of integrated genomic newborn screening

    Principal investigator: Judit Garcia Villoria.
    Funder: Instituto de Salud Carlos III (ISCIII).
    Duration: 01/01/2025 - 01/01/2026

  • Function and therapeutic potential of RNA helicases and miR-122a-5p in liver regeneration and cancer

    Principal investigator: Manuel Morales Ruiz.
    Funder: Agencia Estatal de Investigacion (AEI).
    Code: PID2022-138243OB-I00.
    Duration: 01/10/2024 - 31/03/2026

  • Novel industrially scalable nanotherapies to treat portal hypertension and liver fibrosis in humans

    Principal investigator: Wladimiro Jimenez Povedano.
    Funder: Agencia Estatal de Investigación.
    Code: PDC2022-133780-C22.
    Duration: 01/12/2022 - 31/08/2025

  • Grup de recerca traslacional en noves estratègies de diagnòstic i tractament de la malaltia hepàtica

    Principal investigator: Manuel Morales Ruiz.
    Funder: Generalitat de Catalunya.
    Code: 2021-SGR-00881.
    Duration: 01/01/2022 - 30/06/2025

  • Novel immunomodulatory engineered therapeutic strategies for liver diseases: matrix-embedded endothelial cells and macrophage-targeted dendrimer nanoparticles (ENGILIVE)

    Principal investigator: Pedro Melgar Lesmes.
    Funder: Ministerio de Ciencia, Innovación y Universidades.
    Code: PID2021-123426OB-I00.
    Duration: 01/01/2022 - 01/01/2025

  • FXPAC- Fragile X premutation associated conditions: caracterización clínica y análisis de la firma

    Principal investigator: Laia Rodriguez Revenga.
    Funder: Instituto de Salud Carlos III (ISCIII).
    Code: PI21/01085.
    Duration: 01/01/2022 - 31/12/2024

Major founders

The research of this group can be carried out thanks to the funders.